These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 10220606)

  • 1. Economic and cost-effectiveness in evaluating the value of cardiovascular therapies. The impact of the cost-effectiveness study of GUSTO-1 on decision making with regard to fibrinolytic therapy.
    Califf RM; Stump D; Topol EJ; Mark DB
    Am Heart J; 1999 May; 137(5):S90-3. PubMed ID: 10220606
    [No Abstract]   [Full Text] [Related]  

  • 2. Pitfalls in the economic evaluation of thrombolysis in myocardial infarction. The impact of national differences in the cost of thrombolytics and of differences in the efficacy across patient subgroups.
    Lorenzoni R; Pagano D; Mazzotta G; Rosen SD; Fattore G; De Caterina R; Gensini G
    Eur Heart J; 1998 Oct; 19(10):1518-24. PubMed ID: 9820990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bayesian cost-effectiveness analysis. An example using the GUSTO trial.
    Fryback DG; Chinnis JO; Ulvila JW
    Int J Technol Assess Health Care; 2001; 17(1):83-97. PubMed ID: 11329847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early thrombolysis for the treatment of acute myocardial infarction: a systematic review and economic evaluation.
    Boland A; Dundar Y; Bagust A; Haycox A; Hill R; Mujica Mota R; Walley T; Dickson R
    Health Technol Assess; 2003; 7(15):1-136. PubMed ID: 12773258
    [No Abstract]   [Full Text] [Related]  

  • 5. Tissue plasminogen activator was cost-effective compared to streptokinase in only selected patients with acute myocardial infarction.
    Kent DM; Vijan S; Hayward RA; Griffith JL; Beshansky JR; Selker HP
    J Clin Epidemiol; 2004 Aug; 57(8):843-52. PubMed ID: 15485737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emergent decision-making: defining the patient perspective.
    Knudtson ML
    Can J Cardiol; 2005 Apr; 21(5):433-4. PubMed ID: 15861261
    [No Abstract]   [Full Text] [Related]  

  • 7. Cost-effectiveness of intravenous thrombolytic drugs for acute myocardial infarction.
    Naylor CD; Bronskill S; Goel V
    Can J Cardiol; 1993; 9(6):553-8. PubMed ID: 8221354
    [No Abstract]   [Full Text] [Related]  

  • 8. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction.
    Mark DB; Hlatky MA; Califf RM; Naylor CD; Lee KL; Armstrong PW; Barbash G; White H; Simoons ML; Nelson CL
    N Engl J Med; 1995 May; 332(21):1418-24. PubMed ID: 7723799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A cost-effectiveness model of thrombolytic therapy for acute myocardial infarction.
    Kalish SC; Gurwitz JH; Krumholz HM; Avorn J
    J Gen Intern Med; 1995 Jun; 10(6):321-30. PubMed ID: 7562123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An independently derived and validated predictive model for selecting patients with myocardial infarction who are likely to benefit from tissue plasminogen activator compared with streptokinase.
    Kent DM; Hayward RA; Griffith JL; Vijan S; Beshansky JR; Califf RM; Selker HP
    Am J Med; 2002 Aug; 113(2):104-11. PubMed ID: 12133748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interpreting results from thrombolytic megatrials: distinguishing fact from fiction.
    Brophy JM
    Can J Cardiol; 1996 Jan; 12(1):89-92. PubMed ID: 8595575
    [No Abstract]   [Full Text] [Related]  

  • 12. Stratified cost-effectiveness analysis: a framework for establishing efficient limited use criteria.
    Coyle D; Buxton MJ; O'Brien BJ
    Health Econ; 2003 May; 12(5):421-7. PubMed ID: 12720259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medical decision making in the choice of a thrombolytic agent for acute myocardial infarction. Quebec Acute Coronary Care Working Group.
    Brophy JM; Joseph L; Theroux P
    Med Decis Making; 1999; 19(4):411-8. PubMed ID: 10520679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient reperfusion preferences in acute myocardial infarction: mortality versus stroke, benefits versus costs, high technology versus drugs.
    Tsui W; Pierre K; Massel D
    Can J Cardiol; 2005 Apr; 21(5):423-31. PubMed ID: 15861260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Evaluation of the cost-effectiveness of thrombolytic therapy in acute myocardial infarct using tissue plasminogen activator or streptokinase:the Italian perspective].
    Lorenzoni R; Fattore G; Gensini G
    G Ital Cardiol; 1997 Jul; 27(7):721-6. PubMed ID: 9303862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacoeconomic aspects of treatment of acute myocardial infarction with thrombolytic agents.
    Woo KS; White HD
    Pharmacoeconomics; 1993 Mar; 3(3):192-204. PubMed ID: 10172049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myocardial infarction, thrombolytic therapy, and economics.
    Shander D
    Clin Cardiol; 1993 Nov; 16(11):845. PubMed ID: 8269667
    [No Abstract]   [Full Text] [Related]  

  • 18. Holding GUSTO up to the light. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
    Lee KL; Califf RM; Simes J; Van de Werf F; Topol EJ
    Ann Intern Med; 1994 May; 120(10):876-81; discussion 882-5. PubMed ID: 8154647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies: a health system perspective on thrombolytic therapy for acute myocardial infarction.
    Lewandowski CA; Kahler J
    Am Heart J; 1999 May; 137(5):S94-6. PubMed ID: 10220607
    [No Abstract]   [Full Text] [Related]  

  • 20. Thrombolysis in acute myocardial infarction: t-PA for everyone?
    Reeder GS; Kopecky SL
    Mayo Clin Proc; 1994 Aug; 69(8):796-9. PubMed ID: 8035639
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.